海翔药业
(002099)
| 流通市值：90.70亿 | | | 总市值：90.81亿 |
| 流通股本：16.17亿 | | | 总股本：16.19亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,536,642,734.63 | 1,022,822,870.11 | 486,496,687.33 | 1,860,693,572.54 |
| 营业收入 | 1,536,642,734.63 | 1,022,822,870.11 | 486,496,687.33 | 1,860,693,572.54 |
| 二、营业总成本 | 1,604,601,272.78 | 1,076,138,645.96 | 494,767,487.53 | 1,897,235,398.52 |
| 营业成本 | 1,180,300,468.15 | 792,108,016.28 | 354,451,154.54 | 1,405,933,999.83 |
| 税金及附加 | 26,867,522.61 | 17,058,376.86 | 7,767,988.11 | 33,156,531.03 |
| 销售费用 | 20,390,542.22 | 12,147,042.11 | 6,033,291.39 | 28,676,824.28 |
| 管理费用 | 246,790,855.18 | 163,577,293.84 | 76,547,726.94 | 308,287,485.79 |
| 研发费用 | 91,387,273.79 | 56,758,557.6 | 28,208,897.8 | 116,933,717.28 |
| 财务费用 | 38,864,610.83 | 34,489,359.27 | 21,758,428.75 | 4,246,840.31 |
| 其中:利息费用 | 18,544,700.25 | 12,823,621.35 | 6,157,198.02 | 27,250,265.25 |
| 其中:利息收入 | 23,330,807.59 | 14,007,176.38 | 5,499,572.17 | 50,776,763.03 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -98,748.5 | 3,253,099.03 | 1,130,733.24 | -14,790,765.56 |
| 加:投资收益 | 38,056,475.64 | 51,613,415.22 | 65,925,117.72 | 55,647,202.13 |
| 资产处置收益 | 11,076.14 | 131,922.5 | 128,524.45 | 31,936.39 |
| 资产减值损失(新) | -100,527,576.8 | -79,176,718.2 | -35,415,258.35 | -102,558,171.1 |
| 信用减值损失(新) | -627,642.39 | 897,083.02 | -1,580,035.42 | -2,824,178.31 |
| 其他收益 | 9,961,636.18 | 7,140,138.79 | 3,540,940.18 | 21,010,096.6 |
| 四、营业利润 | -121,183,317.88 | -69,456,835.49 | 25,459,221.62 | -80,025,705.83 |
| 加:营业外收入 | 4,615,712.38 | 3,249,415.66 | 1,247,127.9 | 5,682,418.28 |
| 减:营业外支出 | 2,276,823.89 | 1,645,396.95 | 592,916.33 | 9,747,736.73 |
| 五、利润总额 | -118,844,429.39 | -67,852,816.78 | 26,113,433.19 | -84,091,024.28 |
| 减:所得税费用 | 17,879,627.97 | -3,350,088.26 | -189,410.07 | 9,663,346 |
| 六、净利润 | -136,724,057.36 | -64,502,728.52 | 26,302,843.26 | -93,754,370.28 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -136,724,057.36 | -64,502,728.52 | 26,302,843.26 | -93,754,370.28 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -136,132,609.84 | -64,037,951.66 | 26,446,414.59 | -91,075,551.15 |
| 少数股东损益 | -591,447.52 | -464,776.86 | -143,571.33 | -2,678,819.13 |
| 扣除非经常损益后的净利润 | -183,339,226.47 | -124,324,904.51 | -43,244,768.17 | -136,616,197.47 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.09 | -0.04 | 0.02 | -0.06 |
| (二)稀释每股收益 | -0.09 | -0.04 | 0.02 | -0.06 |
| 八、其他综合收益 | 395,371.61 | 395,371.61 | - | 14,373,444.92 |
| 归属于母公司股东的其他综合收益 | 395,371.61 | 395,371.61 | - | 14,373,444.92 |
| 九、综合收益总额 | -136,328,685.75 | -64,107,356.91 | 26,302,843.26 | -79,380,925.36 |
| 归属于母公司股东的综合收益总额 | -135,737,238.23 | -63,642,580.05 | 26,446,414.59 | -76,702,106.23 |
| 归属于少数股东的综合收益总额 | -591,447.52 | -464,776.86 | -143,571.33 | -2,678,819.13 |
| 公告日期 | 2026-10-28 | 2026-08-29 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |